Nanobac Pharmaceuticals Company Insiders
| NNBP Stock | USD 0.0001 0.00 0.00% |
Nanobac Pharmaceuticals employs about 1 people. The company is managed by 4 executives with a total tenure of roughly 40 years, averaging almost 10.0 years of service per executive, having 0.25 employees per reported executive. Discussion of Nanobac Pharmaceuticals' management performance can provide insight into the enterprise performance.
| John Stanton Chairman Chairman of the Board, CEO, CFO |
Nanobac |
Nanobac Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3684) % which means that it has lost $0.3684 on every $100 spent on assets. This is way below average. Nanobac Pharmaceuticals' management efficiency ratios could be used to measure how well Nanobac Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Nanobac Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 03/01/2025, Return On Equity is likely to grow to 2.63, though Return On Tangible Assets are likely to grow to (92.96). As of 03/01/2025, Change To Liabilities is likely to grow to about 632.9 K, while Total Current Liabilities is likely to drop slightly above 4.6 M.As of 03/01/2025, Net Loss is likely to drop to about (7.9 M)
Nanobac Pharmaceuticals Workforce Comparison
Nanobac Pharmaceuticals Incorporated is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 861. Nanobac Pharmaceuticals adds roughly 1.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Nanobac Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Nanobac Pharmaceuticals Price Series Summation is a cross summation of Nanobac Pharmaceuticals price series and its benchmark/peer.
Nanobac Pharmaceuticals Notable Stakeholders
A Nanobac Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nanobac Pharmaceuticals often face trade-offs trying to please all of them. Nanobac Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nanobac Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John Stanton | Chairman of the Board, CEO, CFO | Profile | |
| Benedict Maniscalco | Medical Research | Profile | |
| Olavi Kajander | Chief OY | Profile | |
| Neva Ciftcioglu | Director CoFounder | Profile |
About Nanobac Pharmaceuticals Management Performance
The success or failure of an entity such as Nanobac Pharmaceuticals often depends on how effective the management is. Nanobac Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nanobac management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nanobac management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (97.85) | (92.96) | |
| Return On Capital Employed | 9.33 | 9.79 | |
| Return On Assets | (1.05) | (1.10) | |
| Return On Equity | 2.51 | 2.63 |
Nanobac Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Nanobac Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nanobac Pharmaceuticals within its industry.Nanobac Pharmaceuticals Manpower Efficiency
Return on Nanobac Pharmaceuticals Manpower
| Revenue Per Employee | 17.6K | |
| Revenue Per Executive | 4.4K | |
| Net Loss Per Employee | 6.6M | |
| Net Loss Per Executive | 1.6M |
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.